Management Team
& Board of Directors

Imhotex is managed by a team of experienced drug development professionals.

Management Team

Anthony W. Segal


Chief Executive Officer

Emeritus Professor of Medicine, UCL.

Tony trained in medicine at the University of Cape Town before moving to London where he specialized as a consultant physician in Gastroenterology and Immunodeficiency, and where he trained in Biochemistry. He held the Charles Dent Chair of Medicine at UCL between 1986 and 2020. His academic research led to the discovery of the NOX electron transport chains and the discovery of the causes of Chronic Granulomatous Disease (CGD) and of Crohn’s disease. He jointly founded University Diagnostics (sold to LGC), Inpharmatica (sold to Galapagos NV) and Arrow Therapeutics (sold to AstraZeneca).

David J. Grainger



After spending 15 years at Cambridge University leading an internationally-recognised laboratory investigating the causes of coronary heart disease, David founded Funxional Therapeutics, where he became the Chief Scientific Officer, developing FX125L, a novel anti-inflammatory agent for the treatment of asthma and other diseases with a chronic inflammatory component. Following the sale of FX125L in July 2012, David joined Index Ventures as a Venture Partner, where he was responsible for the creation of a number of biotech companies including XO1 (which was sold to Janssen Pharmaceuticals in 2015), Morphogen-IX, Critical Pressure and Divide & Conquer. In February 2016, David co-founded Medicxi  a spin-out managing the legacy life sciences portfolio of Index Ventures. Here, he holds the role of Chief Scientific Advisor. In 2018, David and Medicxi co-founded The Foundation Institute of 21st Century Medicine (C21Med) to translate the best science into a pipeline of novel drug candidates and create new life science companies.  

Robert W. Schroff


Chief Operating Officer

Bob has more than 35 years experience developing a range of drug product candidates in both large and small companies. He was VP Research and Development at Funxional Therapeutics, where he was responsible for guiding FX125L from discovery through to Phase 2 clinical trials. Bob was Chief Operating Officer at XO1, Stealthyx and SuperX and is presently Chief Operating Officer at Critical Pressure Ltd.  Bob is responsible for all aspects of development at Imhotex. 

Board of Directors

David J. Grainger

Executive Chairman, Imhotex
Chief Scientific Advisor, Medicxi

Francesco de Rubertis

Director, Imhotex
Partner, Medicxi

Anthony W. Segal

Director & Chief Executive Officer


C/O The Cambridge Partnership
Babraham Research Campus,
Babraham Cambridge, UK
CB22 3FH

For all enquiries